Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: What screening intervals are physicians recommending?

Archives of Internal Medicine

Volumn 170, Issue 11, 2010, Pages 977-986

  Saraiya, Mona ^a   Berkowitz, Zahava ^a   Yabroff, K Robin ^b   Wideroff, Louise ^b   Kobrin, Sarah ^b   Benard, Vicki ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER SCREENING; INTERMETHOD COMPARISON; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIGNETTE; VIRUS EXAMINATION; WART VIRUS; WART VIRUS TEST;

ADULT; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; OFFICE VISITS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT COMPLIANCE; PHYSICIAN'S ROLE; PRACTICE GUIDELINES AS TOPIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR VIRUS INFECTIONS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77953705396     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.134     Document Type: Article

References (46)

1. US Preventive Services Task Force. Screening for Cervical Cancer: Recommendations and Rationale. Rockville, MD: Agency for Healthcare Research and Quality; January 1, 2003. Agency for Healthcare Research and Quality publication 03-515A.
2. Saslow D, Runowicz CD, Solomon D, et al; American Cancer Society. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362.
3. ACOG Committee on Practice Bulletins. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists: Number 45, August 2003: cervical cytology screening. Obstet Gynecol. 2003;102(2):417-427.
4. American College of Obstetricians and Gynecologists. ACOG practice bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: No. 61, April 2005: human papillomavirus. Obstet Gynecol. 2005;105(4):905-918.
5. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 109: cervical cytology screening. Obstet Gynecol. 2009;114(6):1409-1420.
6. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirusbased and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(suppl 10):K29-K41. doi:10.1016/j.vaccine.2008.06.019.
7. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46-52.
8. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66(21):10630-10636. (Pubitemid 44799787)
9. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288(14):1749-1757.
10. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5(1):11. doi:10.1186/1478-7954-5-11.
11. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol. 2009;10(10):935-936.
12. Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007;110(5):1024-1032. (Pubitemid 47312868)
13. Yabroff KR, Saraiya M, Meissner HI, et al. Specialty differences in primary care physician reports of Papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med. 2009;151(9):602-611.
14. ACOG Committee on Gynecological Practice. ACOG committee opinion No. 431: routine pelvic examination and cervical cytology screening. Obstet Gynecol. 2009;113(5):1190-1193.
15. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652-659.
16. Irwin K, Montaño D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006;108(2):397-409. (Pubitemid 44305683)
17. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302(16):1757-1764.
18. Cooper CP, Saraiya M, McLean TA, et al. Report from the CDC: Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J Womens Health (Larchmt). 2005;14(8):670-678.
19. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis. 2008;12(1):1-7.
20. Lomas J, Enkin M, Anderson GM, Hannah WJ, Vayda E, Singer J. Opinion leaders vs audit and feedback to implement practice guidelines: delivery after previous cesarean section. JAMA. 1991;265(17):2202-2207.
21. Soumerai SB. Principles and uses of academic detailing to improve the management of psychiatric disorders. Int J Psychiatry Med. 1998;28(1):81-96. (Pubitemid 28275048)
22. Valente TW, Pumpuang P. Identifying opinion leaders to promote behavior change. Health Educ Behav. 2007;34(6):881-896.
23. Stewart RA, Thistlethwaite J. Routine pelvic examination for asymptomatic women: exploring the evidence. Aust Fam Physician. 2006;35(11):873-877.
24. Huang AJ, Perez-Stable EJ, Kim SE, et al. Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women. J Gen Intern Med. 2008;23(9):1324-1329.
25. Papa D, Moore Simas TA, Reynolds M, Melnitsky H. Assessing the role of education in women's knowledge and acceptance of adjunct high-risk human papillomavirus testing for cervical cancer screening. J Low Genit Tract Dis. 2009;13(2):66-71.
26. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113(3):595-600.
27. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501.
28. Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst. 2009;101(2):88-99.
29. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening: second edition: summary document. Ann Oncol. 2010;21(3):448-458. doi:10.1093/annonc/mdp471.
30. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
31. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597.
32. Ahnang Price R, Frank RG, Cleary PC, Goldie S. Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of a cervical cancer screening test. Poster presented at: Academy Health Annual Research Meeting; June 28, 2009; Chicago, IL.
33. Women in Government. Strategies for eliminating cervical cancer: recommendations for a collaborative approach: findings from the 2005 HPV & Cervical Cancer Summit. 2006. http://www.womeningovernment.org/files/file/ prevention/resources/FINALMANUSCRIPT5-15-06.pdf. Accessed December 15, 2009.
34. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287(18):2372-2381. (Pubitemid 34493200)
35. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619-631.
36. Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med. 2008;168(17):1881-1889.
37. Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2126-2132.
38. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284. doi:10.1136/bmj.a1284.
39. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-498.
40. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111(12):1437-1443.
41. Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making. 2007;27(4):414-422.
42. Shinn E, Basen-Engquist K, Le T, et al. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med. 2004;39(2):404-412.
43. Montaño DE, Phillips WR. Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. Am J Public Health. 1995;85(6):795-800.
44. Veloski J, Tai S, Evans AS, Nash DB. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual. 2005;20(3):151-157.
45. Peabody JW, Liu A. A cross-national comparison of the quality of clinical care using vignettes. Health Policy Plan. 2007;22(5):294-302.
46. Phelan DF, Boitnott JK, Clark DP, Dubay LC, Gravitt P. Utilizing laboratory informatics to assess trends of cervical cancer screening in an east coast health system, 2001-2007. Paper presented at: 137th Annual Meeting of the American Public Health Association; November 9, 2009; Philadelphia, PA.